Medindia

X

NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer

Sunday, June 6, 2010 General News J E 4
Advertisement
Phase 2 Data Highlighted in Oral Abstract Session of 2010 American Society of Clinical Oncology Annual Meeting

Nektar Investor Inquiries:

Jennifer Ruddock/Nektar Therapeutics

(650) 631-4954

Susan Noonan/S.A. Noonan Communications

(212) 966-3650

Nektar Media Inquiries

Karen Bergman/BCC Partners

(650) 575-1509

Michelle Corral/BCC Partners

(415) 794-8662

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Karmanos Cancer Institute Researchers, Collaborato...
S
AIDS/LifeCycle Begins as 2,400 Hit the Road to Rai...